Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Naltrexone in Disordered Gamblers
NCT02537197Phase 1Completed
- Sponsor
- University of Calgary
- Start
- Apr 2016
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of naltrexone in gambling disorder (GD), sponsored by University of Calgary. Primary endpoint: Abstinence. Started Apr 2016; status: completed.
02
Drugs
naltrexone
03
Conditions
gambling disorder (GD)
Beyond the preview
Go deeper on NCT02537197.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02537197.